Shares of Sotera Health (NYSE:SHC – Get Rating) have been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.83.
→ The “King Of Quants” sees 10X potential… (From Investor Place Media)
A number of research firms have recently issued reports on SHC. Royal Bank of Canada upped their price objective on Sotera Health from $8.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Wolfe Research upgraded Sotera Health from a “peer perform” rating to an “outperform” rating and set a $25.00 target price for the company in a report on Tuesday, January 10th. JPMorgan Chase & Co. upgraded Sotera Health from an “underweight” rating to a “neutral” rating and increased their target price for the company from $6.00 to $18.00 in a report on Monday, January 23rd. Finally, Barclays upgraded Sotera Health from an “underweight” rating to an “overweight” rating and increased their target price for the company from $6.00 to $22.00 in a report on Tuesday, January 10th.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of SHC. Citigroup Inc. raised its position in Sotera Health by 325.9% during the 1st quarter. Citigroup Inc. now owns 80,432 shares of the company’s stock valued at $1,742,000 after purchasing an additional 61,547 shares during the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Sotera Health in the 1st quarter worth approximately $317,000. Bank of Montreal Can raised its position in shares of Sotera Health by 153.7% in the 1st quarter. Bank of Montreal Can now owns 291,140 shares of the company’s stock worth $6,437,000 after acquiring an additional 176,400 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Sotera Health in the 1st quarter worth approximately $139,000. Finally, BlackRock Inc. raised its position in shares of Sotera Health by 7.6% in the 1st quarter. BlackRock Inc. now owns 6,252,520 shares of the company’s stock worth $135,429,000 after acquiring an additional 439,762 shares in the last quarter. Institutional investors own 87.21% of the company’s stock.
Sotera Health Price Performance
NYSE:SHC opened at $17.52 on Friday. The firm has a market capitalization of $4.95 billion, a price-to-earnings ratio of -21.11 and a beta of 2.09. Sotera Health has a 52-week low of $5.78 and a 52-week high of $24.90. The stock has a fifty day moving average of $17.43 and a 200 day moving average of $11.82. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.77 and a current ratio of 0.81.
Sotera Health Company Profile
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company’s sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sotera Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sotera Health wasn’t on the list.
While Sotera Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
